Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.26
INSV's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 0.26 )
INSV' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.26

Equity to Asset -1.60
INSV's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -1.60 )
INSV' s 10-Year Equity to Asset Range
Min: -5.91   Max: 0.95
Current: -1.6

-5.91
0.95
F-Score: 7
Z-Score: -11.55
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -3.15
INSV's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -3.15 )
INSV' s 10-Year Operating margin (%) Range
Min: -889900   Max: 23.72
Current: -3.15

-889900
23.72
Net-margin (%) -38.25
INSV's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -38.25 )
INSV' s 10-Year Net-margin (%) Range
Min: -860000   Max: 23.29
Current: -38.25

-860000
23.29
ROA (%) -46.61
INSV's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -46.61 )
INSV' s 10-Year ROA (%) Range
Min: -681.06   Max: 36.87
Current: -46.61

-681.06
36.87
ROC (Joel Greenblatt) (%) -180.64
INSV's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -180.64 )
INSV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11727.91   Max: 1100
Current: -180.64

-11727.91
1100
Revenue Growth (%) 17.00
INSV's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 17.00 )
INSV' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 188.4
Current: 17

0
188.4
EPS Growth (%) -26.30
INSV's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -26.30 )
INSV' s 10-Year EPS Growth (%) Range
Min: -36.1   Max: 3.1
Current: -26.3

-36.1
3.1
» INSV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with INSV



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1.70
INSV's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 1.70 )
INSV' s 10-Year P/E(ttm) Range
Min: 1.6   Max: 41.33
Current: 1.7

1.6
41.33
P/S 0.77
INSV's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 0.77 )
INSV' s 10-Year P/S Range
Min: 0.55   Max: 269
Current: 0.77

0.55
269
EV-to-EBIT 3.80
INSV's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 3.80 )
INSV' s 10-Year EV-to-EBIT Range
Min: 2.6   Max: 183.1
Current: 3.8

2.6
183.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.20
INSV's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 0.20 )
INSV' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 48.45
Current: 0.2

0.19
48.45
Earnings Yield (Greenblatt) 26.00
INSV's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: 26.00 )
INSV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 38.9
Current: 26

0.5
38.9
Forward Rate of Return (Yacktman) -53.92
INSV's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. INSV: -53.92 )
INSV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -114.7   Max: 14.6
Current: -53.92

-114.7
14.6

Business Description

Industry: »
Compare: » details
InSite Vision Incorporated was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. It is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company is currently focusing its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration (FDA) in April 2007 to treat bacterial conjunctivitis (pink eye). Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin developed as a broad spectrum ocular antibiotic and approved by the FDA in May 2009 to treat bacterial conjunctivitis (pink eye). ISV-502 is a fixed combination of azithromycin and dexamethasone in the DuraSite vehicle for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis) for which there is no FDA-approved treatment. ISV-305 is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. ISV-303 is a DuraSite formulation of bromfenac in development for the treatment of post operative inflammation and eye pain. The Company is currently preparing an Investigational New Drug Application (IND) for this product candidate. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INSV

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide